The Claim

Intravenous administration of therapeutic doses of sodium selenite (>1 mg/day) in critically ill cancer and cardiac patients increases circulating selenoprotein P (SELENOP) concentrations beyond the previously established upper limit of 7 mg/L, with some values exceeding 10 mg/L, indicating that SELENOP can serve as a dynamic biomarker for supraphysiological selenium exposure in clinical settings.

Source: Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
68score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Intravenous sodium selenite at doses greater than 1 mg per day in critically ill cancer and cardiac patients raises blood levels of selenoprotein P above 7 mg/L, with some measurements exceeding 10 mg/L, demonstrating that selenoprotein P responds to high selenium exposure in these patients.

See the scientific wording

Intravenous administration of therapeutic doses of sodium selenite (>1 mg/day) in critically ill cancer and cardiac patients increases circulating selenoprotein P (SELENOP) concentrations beyond the previously established upper limit of 7 mg/L, with some values exceeding 10 mg/L, indicating that SELENOP can serve as a dynamic biomarker for supraphysiological selenium exposure in clinical settings.

Why this might work

When selenium is given directly into the bloodstream, the liver takes it up and uses it to make more of a special protein called selenoprotein P, which then floods into the blood. This protein keeps being made even when levels go higher than ever seen before, because the liver doesn't stop at the old maximum — it keeps producing more as long as selenium is available.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite

    When very high doses of selenium are given through an IV to very sick patients, a blood protein called SELENOP goes way higher than doctors thought it could — up to over 10 mg/L — proving it can track extreme selenium levels.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.